BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)

Group 1 - Bristol-Myers Squibb Company (NYSE:BMY) is considered one of the best growth stocks under $50, with a Hold rating maintained by BMO Capital analyst Evan Seigerman and a price target of $47.00 [1][2] - The performance of Cobenfy, a new product from Bristol-Myers Squibb, has shown stable growth with a modest percentage increase in weekly prescription rates, although it has not met the higher expectations for H2 2025 [2] - Revenue estimates for Cobenfy in Q3 are slightly below consensus estimates, which supports the Hold rating [2] Group 2 - Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering advanced medicines for serious diseases across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience [3]